A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in doctors’ offices. Originally developed as a treatment for type 2 diabetes, ...
Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...
The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
While there’s no quick fix for these rising healthcare costs, there is a smarter plan that balances employee needs with ...
Discover how GLP-1 drugs like Ozempic and Mounjaro are transforming the fight against obesity. Learn the science, the risks, and the real-world results from experts on the front lines. Take control of ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Obesity treatment is hurtling into a new era: once-a-week GLP-1 injections are edging toward the dramatic results of bariatric surgery, yet many of us remain tethered to the very habits that fuel ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...
Demand for GLP-1 drugs is causing spending on traditional drugs to grow at a faster clip than spending on specialty drugs, according to new research. That could put further stress on employers and ...
Among four classes of drugs used to treat type 2 diabetes (T2D), the GLP-1 receptor agonists (RAs) appeared to be most protective against major adverse cardiovascular events (MACE) — followed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback